Stifel initiates Sutro Biopharma stock with buy on ADC platform By Investing.com

Stifel has initiated coverage on Sutro Biopharma Inc. (NASDAQ:STRO) with a buy rating and a $48.00 price target, citing its promising antibody-drug conjugate (ADC) platform. The company's stock is currently trading at $24.15, suggesting a potential upside of 99%, and InvestingPro analysis indicates it is undervalued. Sutro Biopharma also recently received an overweight rating from Barclays, further highlighting analyst interest in its prospects.